Serial procalcitonin is reported to be useful to titrate duration of antibiotic therapy in the non critically ill patient with pneumonia. The aim of this study was to examine the relationship between antibiotic therapy and serial serum procalcitonin concentrations in a cohort of critically ill septic patients and examine for any differences between culture positive (CP) and culture negative (CN) sepsis. Seventy-five critically ill patients with suspected sepsis were enrolled in this prospective observational study. Serial procalcitonin and C-reactive protein assays were measured on days one, three, five, seven, 10 and 14. The mean duration of antibiotic therapy was similar in the two groups (10.4±5.1 (CP) vs. 8.4±5.1 (CN) days, P=0.09). Serum procalcitonin concentrations were significantly higher at baseline in the CP than the CN group (14.9±22.9 vs. 6.8±21.5 ng/ml, P=0.04). During the study period, serum concentrations of procalcitonin and C-reactive protein declined in both groups. Serum procalcitonin consistently remained higher in the CP group (P<0.05) and did not return to normal values. In the CN group, procalcitonin concentrations fell below 0.5 only on day 10. There was no significant difference in C-reactive protein profile between the two groups. Four patients in the CP group (11%) had relapse of sepsis. The mean procalcitonins in the relapsed subgroup were lower than those in the remission subgroup (P=0.02). Therapy for proven or presumed infections was associated with declining serum procalcitonin and C-reactive protein in critically ill septic patients. The marked variability and overlap in plasma profile of these markers between CP and CN sepsis makes it difficult to define a nadir plasma concentration at which one can recommend discontinuation of antibiotic therapy.
Defining the optimal duration of antimicrobial therapy for sepsis is marked by continuing controversy 1 .
Current textbooks recommend treatment durations ranging from three to seven days depending on the clinical status of the patient and the likelihood of infections. A recent worldwide survey of practice of antibiotic prescription in the critically ill confirmed this finding 2 . The efficacy and safety of these recommendations have never been formally evaluated. While empiric treatment regimens have been developed, little effort has been directed toward prospective analysis of appropriate antibiotic treatment duration.
The advent of biomarkers to diagnose bacterial sepsis such as C-reactive protein (CRP) and procalcitonin (PCT) has provided clinicians with a new tool by which antibiotic therapy could be titrated. Serum PCT concentrations have been advocated as a guide to initiation of therapy in lower respiratory tract infections 3 and a recent open study by the same group in patients with community-acquired pneumonia suggested that in patients on antibiotics a serum [PCT] >0.5 µg/l could be used as an indication to continue antibiotic therapy, while a value <0.25 µg/l (return to normal values) was suggested as a marker for discontinuing therapy 4 .
The use of CRP as biomarker to guide antibiotic therapy has been largely confined to the paediatric population and have provided mixed results [5] [6] [7] . Data from ehl et al 5 and Jaswal et al 6 suggest that CRP can be used as a parameter to identify the time point when antibiotic treatment can safely be discontinued in a defined major subgroup of neonates treated for suspected bacterial infection. on the other hand, data from engle et al 7 clearly suggest that PCT and CRP were not superior to neutrophil values for guiding antibiotic duration. In adult critically ill patients with ventilator-associated pneumonia, CRP has been shown to correlate with bacterial load and appropriate antibiotic therapy although the correlation was weak 8 .
The rationale behind the use of serum CRP and PCT for tailoring duration of antibiotic therapy is that bacterial infections are the predominant cause of elevations in serum PCT. Hence the use of declining serum concentrations of these inflammatory markers of sepsis as an indication of resolution of bacterial sepsis and therefore cessation of antibiotic therapy is appealing and formed the basis of studies by Christ-Crain et al 3 . of note however, is that patients enrolled into the study of Christ-Crain et al are different from the one seen in the intensive care unit (ICU) because the former often had clear-cut diagnosis of sepsis and did not have other organ dysfunction.
In contrast, both PCT and CRP have limited specificity and sensitivity in the diagnosis of sepsis in the critically ill patient [9] [10] [11] . We have shown that serum CRP and PCT have limited sensitivity and specificity in diagnosing sepsis in neurotrauma and subarachnoid haemorrhage 12 . Furthermore, the presence of systemic inflammatory response syndrome (SIRS) and organ dysfunction have been shown to be associated with elevations in serum PCTs independently of sepsis 13 . Therefore the question remains whether serum PCT may serve as an effective guide for determining duration of antimicrobial therapy in the critical care environment.
given the lack of prospective studies on the duration of antibiotic duration in the critically ill and the absence of sensitive and specific laboratory markers of infection, we designed a prospective study to:
Determine the plasma concentrations and 1.
temporal profile of serial serum PCT and CRP during antibiotic therapy for critically ill patients with suspected sepsis, examine whether serum concentrations of these 2.
biomarkers differ between culture positive (CP) and culture negative (CN) sepsis.
MATeRIALS AND MeTHoDS
The study protocol was approved by the Princess Alexandra Hospital ethics Committee. Informed consent was sought from patients or their next of kin. Adult patients (patients >16 years of age) admitted to intensive care with a diagnosis of suspected sepsis for whom the treating intensivist decided to initiate antibiotic therapy were considered eligible for inclusion into the study. Between July 2004 and December 2005, patients who had been admitted to the ICU in the previous 48 hours with sepsis or those in ICU who were thought to have developed a new sepsis in the previous 48 hours were enrolled. Patient identification was by one of the investigators or the research nurse with the cooperation of the attending physicians. Patients were excluded if they were already on antibiotics for longer than 24 hours prior to admission.
DeFINITIoNS oF STUDy gRoUPS
As noted above, patients with suspected sepsis were enrolled into the study. They were subsequently dichotomised into CP and CN sepsis. Identification of SIRS and sepsis was based on the guidelines developed at the Consensus Conference of the American College of Chest Physicians and the Society of Critical Care Medicine 14 .
"Infection" was defined as a microbial phenomenon characterised by an inflammatory response to the presence of micro-organisms or the invasion of normally sterile host tissue by those organisms.
A patient was considered to have an infection if:
There was documented SIRS, 1.
A diagnostic work-up for an infection was 2.
initiated, There was a positive culture of potentially 3.
pathogenic micro-organisms, There was a statement by the medical team of a 4.
high likelihood of infection, and Antibiotics were commenced. 5.
All of the above criteria had to be met before a patient was considered to have an infection.
The type of infection was documented according to standard definitions of the Centers for Disease Control and Prevention 15 . Pneumonia was diagnosed if radiological infiltrates were evident with a positive sputum culture. Abscesses and peritonitis were diagnosed by ultrasonograph or CT scan or at laparotomy together with growth of pathogenic bacteria from aspirated pus. Urinary infections were diagnosed based on the presence of leukocyte count in the urine and a positive culture. Resolution of infection was defined as resolution of SIRS and recovery of organ function.
ANTIMICRoBIAL THeRAPy
The choice of antimicrobial therapy was determined by the intensivist in conjunction with the infectious diseases specialist based on the clinical picture and the availability of microbiology results. The duration of treatment was determined jointly by the intensivists and the infectious disease specialist and was based on clinical recovery, resolution of SIRS and organ dysfunction. The treating clinicians were blinded to the serum concentration of CRP and PCT.
Adequacy of treatment was assessed on the basis of in vitro bacterial sensitivity, improvement in clinical course and resolution in SIRS and organ dysfunction 16 . A relapse in sepsis was defined as evidence of new sepsis within two weeks of cessation of the previous course of antibiotic necessitating a new course of antibiotics.
All patients received standard supportive care which included sedation and ventilation where appropriate, antibiotic therapy and surgical drainage of infected collections.
Data collection included demographics, vital signs, results of microbiological cultures, antibiotics used and illness severity assessed by Acute Physiology and Chronic Health evaluation (APACHe) II and the sequential organ failure assessment (SoFA) scores 16 . Samples of blood were collected at admission and on days one, three, five, seven, 10 and 14 if applicable for routine blood tests which included a full blood count, CRP and a biochemical profile.
Assay of PCT and CRP
The serum remaining from blood samples collected for routine investigations were stored at -70°C and used for the assay of PCT and CRP. Plasma PCT concentrations were measured using an immunoassay with a sandwich technique and a chemiluminescence detection system according to the manufacturer's protocol (LumiTest, Brahms Diagnostic, Berlin, germany) 17 . The detection limit for the assay is 0.1 ng/ml and the coefficient of variation, between 1 to 1000 ng/ml, is 5 to 10%. The assay is also free of interference from the antibiotics, sedatives and vasoactive agents that are commonly used in the intensive care unit. Serum CRP was measured in the hospital laboratory by rate nephelometry using the Beckman IMMAge Immunochemistry system.
oUTCoMe MeASUReS
The primary outcome measure was the temporal profile and serum concentrations of CRP and PCT over the course of antibiotic therapy and their relationship to clinical and microbiological resolution of infection, and duration of antibiotic therapy.
STATISTICAL MeTHoDS
Analysis was performed by SAS, version for Windows 9.1 (SAS Institute, Cary, NC, USA). Daily levels of PCT and CRPs were investigated to determine how well they could discriminate between when a patient was on antibiotic treatment and when they were not. Sensitivities and specificities were estimated via a logistic regression model and generalised estimating equations to account for the repeated measures taken throughout the study. Due to the skewed nature of the PCT data it was log transformed prior to statistical analysis. A linear mixed model was used to model (log) PCT over the study duration by infection status. An autoregressive correlation structure was used to model the repeated (log) PCT observations within patients.
ReSULTS
Seventy-five patients with suspected sepsis were enrolled into the study. of these, 37 were subsequently deemed to have CP sepsis, while the other 38 patients were deemed to have CN sepsis. Patients were deemed to have CN sepsis based on clinician assessment and absence of a positive culture of potentially pathogenic micro-organisms. In the CP group, the number of patients for follow-up on each of the study days were as follows: D1-37, D3-37, D5-34, D7-30, D10-29 and D14-24; in the CN group, the corresponding numbers were as follows: D1-38, D3-35, D5-35, D7-30, D10-28 and D14-17. The demographic details of the whole cohort are provided in Table 1 . The distribution of the various sites of infection are presented in Table 2 . 
Antibiotic therapy
The mean duration of antibiotic use was not statistically different between the patients with CP sepsis (10.4±5.1 days) and CN sepsis (8.4±5.1 days, P=0.09). All patients in the CP septic cohort received appropriate therapy based on in vitro sensitivity.
Serum PCT and CRP kinetics
The mean plasma concentrations of PCT and CRP over the course of the study for the whole cohort are illustrated in Figure 1 . Both mean PCT and mean CRP were elevated at baseline and peaked on D3 followed by a gradual fall in serum concentrations. Mean serum PCT was just elevated (0.69) above normal (0.5) on D14, while CRP remained elevated even at D14.
The serum PCT and CRP profile for the CP and CN groups are presented in Table 3 . Serum PCT concentrations were significantly higher at baseline (14.9±22.9 vs. 6.8±21.5 ng/ml, P=0.04) in the CP group compared to the CN group and consistently remained higher in the CP group throughout the study period (P <0.05). In both groups, PCT peaked on D3. In the CP group, PCT did not return to normal values (<0.5 ng/ml), while in the CN group, PCT concentrations fell below 0.5 on D10.
In contrast, serum CRP followed a different concentration profile compared with PCT. There were no significant differences between CP and CN groups with respect to plasma concentrations at any stage, levels were higher in the infectious group only till D5 and did not return to normal in either group even by D14.
Evaluation of serum PCT and CRP profile in patients who had a relapse of sepsis
In the CP group, four patients (11%) had a new episode of sepsis necessitating a new course of antibiotics (relapse group). The other 33 (89%) were classified as the remission group. The mean PCT values in the relapsed group were lower than those in the remission group (P=0.02). There was no difference in serum CRP profile between patients in the remission group and the relapsed group. None of the patients in the CN group was diagnosed to have a septic relapse. Can a specific serum concentration of PCT be used to determine whether antimicrobials could be discontinued?
Despite the difference in serum PCT concentrations between patients with infection and those without infection, there was significant overlap between the distributions of (log) PCT by CP status throughout the study duration, thus making it impossible to define a nadir concentration of PCT at which antibiotic therapy could be safely discontinued. The sensitivities and specificities for various thresholds of serum PCT and for a CRP >100 mg/l, which might indicate the presence of ongoing infection, are presented in Table 4 .
DISCUSSIoN
The principal finding of this study was that both serum PCT and CRP were elevated in a heterogeneous cohort of critically ill patients with suspected sepsis. While antibiotic therapy and resolution of sepsis were associated with a reduction in plasma PCT and CRP concentrations, there was no clear time point at which the values returned to normal levels. There was a trend towards higher concentrations in patients with CP sepsis, however there is marked variability in the plasma concentrations resulting in overlap between the two groups.
In the last decade, serum procalcitonin (PCT) has emerged as a new diagnostic marker of severe bacterial infection and septic shock in both adults and in children, irrespective of their immunological status, and is possibly superior to the more conventional biological markers as an indicator of bacterial infection 9, 10, 18, 19 . Absolute values and sequential changes in PCT in response to therapy have also been reported to have prognostic significance in a variety of clinical states [20] [21] [22] . Persistent elevations of PCT are associated with increased length of stay, multiple organ dysfunction and mortality.
Comparison with previously published data
Recently, a large single-centre study has concluded that nadir PCT concentrations of less than 0.25 µg/l can be used to titrate the duration of antibiotic therapy in patients with community-acquired pneumonia 4 . Viallon et al have shown that serum PCT levels decrease with antibiotic therapy in acute bacterial meningitis and suggested that serial concentrations may be of benefit in assessing treatment efficacy 23 . Smith et al arrived at similar conclusions in patients with melioidosis 24 . The data from these suggest that in discrete clinical infections, PCT may be of benefit in assessing efficacy of treatment. A recent randomised controlled trial examining the utility of serum PCT for discontinuation of antibiotic therapy in septic critically ill patients found a reduced duration of antibiotic therapy in the PCT group compared to the conventional group 25 . They propose a drop in PCT of >90% from baseline as an indicator of resolution of sepsis. However, the study protocol did not detail how infection was diagnosed, a number of infectious categories were excluded and nearly 20% of patients had a normal PCT on admission. We suggest, based on our data, that in a heterogeneous cohort of critically ill septic patients, serial PCT may not have the same predictive value and that recommendation of discontinuation of therapy cessation based on serum concentrations may be premature.
The reasons for the drop in sensitivity in the critically ill patient include: 1) a number of noninfectious conditions such as trauma, burns, cardiac surgery and pancreatitis result in elevation of serum PCT [26] [27] [28] [29] , 2) PCT release is not driven directly by bacterial load, but more by systemic inflammation 30 , 3) there is no linear relationship between systemic inflammation and serum PCT 31 , 4) in critically ill patients with organ dysfunction, PCT concentrations are related to the severity of organ dysfunction irrespective of its underlying aetiology, thus in a heterogeneous cohort such as seen in this study, the presence of organ dysfunction reduces the sensitivity of PCT 13 , 5) localised infections may not give rise to elevations in serum PCT concentrations 10 , 6) the cutoff value of PCT giving the optimum sensitivity and specificity for the diagnosis of infection varies with different conditions 11 and 7) a falling PCT level in response to antibiotic therapy does not necessarily imply eradication of infection, but merely that the inflammatory response is under control.
The study enrolled critically ill patients with suspected sepsis and only 50% were felt to have clear evidence of sepsis as defined by a positive culture. The question remains whether the CN group is a 'true septic' or merely a non-infectious SIRS cohort. The diagnosis of infection and the decision to initiate antibiotic therapy was made by the treating clinician replicating 'normal clinical practice'. Furthermore, the clinicians were blinded to serum PCT and CRP concentrations. We chose a variety of septic states as opposed to other data which have looked at discrete entities such as community-acquired pneumonia. It could be argued that the inflammatory responses may be different in each, thus a heterogeneous cohort such as ours may not be sensitive enough to detect the usefulness of PCT and CRP. The two groups also differed in the sites of infection which may influence the inflammatory response and concentrations of biomarkers. We submit that there is a possibility of a type 2 error when dealing with small sample sizes. A post hoc sample size calculation based on our results would suggest that one would need to enrol 800 patients (400 in each arm) to detect a difference in antibiotic duration therapy of one day or to detect a halving of the relapse rate. We used SIRS criteria for identifying possible sepsis. They have been criticised for being too sensitive 32 , however they provide uniformity in inclusion criteria and recent data suggest that SIRS criteria use is widespread in clinical trials of sepsis 33 . Despite the above, both in the group as a whole and in those with CP sepsis, serum PCT did not decline to baseline values despite conventional duration of antibiotic therapy and in whom a substantial proportion (89%) had clinical cure of sepsis.
In conclusion, in this preliminary study, both serum PCT and CRP were found to be elevated in a heterogeneous cohort of critically ill patients with suspected sepsis. While CP patients tended to have higher plasma concentrations of PCT, the presence of systemic inflammation and multiple organ dysfunction results in marked variability in the plasma concentrations of PCT and CRP which leads to a significant overlap between the two groups. This makes it difficult to define a nadir plasma concentration of these markers at which one can recommend discontinuation of antibiotic therapy. We recommend that future studies attempting to optimise duration of antibiotic therapy utilising these biomarkers in septic critically ill patients will need to consider large sample sizes to account for the heterogeneity of patients and establish unambiguous clinical and microbiological definitions of infection and treatment efficacy.
